Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBRACE: CYB003 in Major Depressive Disorder
NCT06793397Phase 3Recruiting
- Sponsor
- Cybin Inc.
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Orthosteric Ligands
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of CYB003 in major depressive disorder (MDD) (3 arms), sponsored by Cybin Inc. Primary endpoint: Montgomery-Asberg Depression Rating Scale at Day 84. Started Dec 2025; status: recruiting.
02
Drugs
CYB003
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06793397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06793397.